Iron Supplementation–Induced Phosphaturic Osteomalacia: FGF23 is the Culprit

Journal of Bone and Mineral Research

Volumn 33, Issue 3, 2018, Pages 540-542

  Urbina, Tomas ^a,b   Belkhir, Rakiba ^a,b   Rossi, Geoffrey ^a,b   Carbonnel, Franck ^a   Pavy, Stephan ^a,b   Collins, Michael ^a   Mariette, Xavier ^a,b   Seror, Raphaèle ^a,b  

^a Hôpitaux Universitaires Paris Sud   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; FERRIC CARBOXYMALTOSE; FERROUS SULFATE; FIBROBLAST GROWTH FACTOR 23; INFLIXIMAB; OCTREOTIDE; PHOSPHATE; PHOSPHORIC ACID; FIBROBLAST GROWTH FACTOR; IRON;

ADULT; BONE DENSITY; CALCIUM BLOOD LEVEL; CASE REPORT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CREATININE URINE LEVEL; CROHN DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMORAL HEAD FRACTURE; HIP PAIN; HIP RADIOGRAPHY; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; IRON THERAPY; JOINT LIMITATION; LEG EDEMA; LETTER; LUMBAR SPINE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; PAIN SEVERITY; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PHOSPHATURIA; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SHOULDER PAIN; STERNUM; TREATMENT DURATION; URINALYSIS; VITAMIN BLOOD LEVEL; WHOLE BODY PET; DIETARY SUPPLEMENT; GAIT; INFLAMMATORY BOWEL DISEASE; PAIN; STRESS FRACTURE;

DIETARY SUPPLEMENTS; FIBROBLAST GROWTH FACTORS; FRACTURES, STRESS; GAIT; HUMANS; HYPOPHOSPHATEMIA; INFLAMMATORY BOWEL DISEASES; IRON; OSTEOMALACIA; PAIN;

EID: 85041672951     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.3369     Document Type: Letter

References (7)

1. Bartko J, Roschger P, Zandieh S, Brehm A, Zwerina J, Klaushofer K. Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J Bone Miner Res. Forthcoming. 2017 Oct 25. DOI:10.1002/jbmr.3319.
2. Okada M, Imamura K, Fuchigami T, et al. Two cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide. Nihon Naika Gakkai Zasshi. 1982; 71:1566–72.
3. Yamamoto S, Okada Y, Mori H, Fukumoto S, Tanaka Y. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric-oxide. Intern Med. 2012; 51(17):2375–8.
4. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphatemic osteomalacia. Ann Clin Biochem. 2009; 46(Pt 2): 167–9.
5. Gravesen E, Hofman-Bang J, Mace ML, Lewin E, Olgaard K. High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol. 2013; 14:281.
6. Imamura K. Effects of intravenous administration of iron preparations on the metabolism of phosphorus. Comparative study of 3 iron preparations. Fukuoka Igaku Zasshi. 1984; 75(6):316–26.
7. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015; 2015:468675.